3rd Pavia international symposium on advanced kidney cancer

Camillo Porta, Sergio Bracarda

Research output: Contribution to journalArticlepeer-review


Kidney cancers' natural history has radically changed in the past few years, due to the development of novel targeted agents. Despite these improvements, several unanswered questions still remain on the table, regarding the best first-line treatment, the ideal sequence of treatments, the management of specific subgroups of patients (e.g., elderly patients or those with comorbidities) and the relevance of prognostic factors, among many others. To foster discussions among clinicians and investigators working in this field, and to exchange different viewpoints concerning the newest advances in kidney cancer pathogenesis and treatment, the 3rd Pavia International Symposium on Advanced Kidney cancer was held in Pavia (Italy) between 30 June and 1 July 2011. The aim of this report is to summarize the most significant advances in the different disciplines applied to advanced kidney cancer, which were presented and discussed during the meeting, and how these advances will be changing the perspective of patients with this disease.

Original languageEnglish
Pages (from-to)445-453
Number of pages9
JournalExpert Opinion on Pharmacotherapy
Issue number3
Publication statusPublished - Feb 2012


  • Kidney cancer
  • Prognostic factors
  • Targeted agents
  • Therapeutics

ASJC Scopus subject areas

  • Pharmacology (medical)
  • Pharmacology


Dive into the research topics of '3rd Pavia international symposium on advanced kidney cancer'. Together they form a unique fingerprint.

Cite this